Brief: Alector Announces Completion Of Enrollment In The Invoke-2 Phase 2 Clinical Trial Of Al002
07/09/2023 13:12
Sept 7 (Reuters) - ALECTOR INC ALEC.O :
* ALECTOR ANNOUNCES COMPLETION OF ENROLLMENT IN THE INVOKE-2
PHASE
2 CLINICAL TRIAL OF AL002, A TREM2 MONOCLONAL ANTIBODY, IN
INDIVIDUALS WITH EARLY ALZHEIMER’S DISEASE
* ALECTOR INC - DATA FROM TRIAL ARE EXPECTED IN Q4 OF 2024
Source text for Eikon: ID:nGNX31R9SX
Further company coverage: ALEC.O
(Reporting by ArsheeyaSingh Bajwa)
((ArsheeyaSingh.Bajwa@thomsonreuters.com;))